Chemotherapy of hormone-resistent cancer of the prostate


Cite item

Full Text

Abstract

A total of 59 patients with hormone-resistent prostatic cancer (HDPC) treated in 1999-2004 entered the trial. Three schemes of first-line chemotherapy were examined for clinical efficacy and toxicity in the above patients. Anticancer combined treatment vinorelbin + cycloplatam was given to 23 patients, mitoxantron + prednisolone - to 23 patients, mitoxantron+cysplatin+prednisolone - to 13 patients. The latter scheme was most effect and toxic. Partial regression of metastases and a 50% decrease in the initial PCA level were seen in 23% cases. Vinorelbin+cycloplatam was less effective and toxic: partial regression of metastases - 13%, PSA regression - 17.4%. The least efficacy and toxicity were observed in the treatment with mitoxantron+prednisolone - 8.7%. Thus, the above first-line HDPC therapy was most effective but has the highest toxicity in using the scheme mitoxantron+cysplatin+prednisolone.

References

  1. Давыдов М. И., Аксель Е. М. Злокачественные новообразования в России и странах СНГ в 2001 г. 2003. 7-10; 100- 102.
  2. Матвеев Б. П. Клиническая онкоурология. М 2003 435- 601.
  3. Joseph A., Smith J., Soloway M. S. et al. Complications of advanced prostate cancer. Urology 1999; 54 (suppl. 6A): 8-14.
  4. Rosendahl I., Kiebert G. M., Curran D. et al. Quality-adjusted survival (Q-TWIST) analysis of EORTC trial 30853. Comparing goserelin acetate and flutamide with bilateral orhiectomy in patient with metastatic prostate cancer. Prostate 1999' 38 (2Y 100-109.
  5. Корякин О. Б., Свиридова Т. В. Распространенный рак предстательной железы: результаты лечения различными методами. В кн.: Пленум Правления Российского о-ва урологов. М.; 1999. 67.
  6. Petrylak D. P. Chemotherapy for the treatment of hormone-refractory prostate cancer. Eur. Urol. Suppl. 2002; 1 (2): 15-23.
  7. Hellawel G. O., Turner G. D., Davies D. E. et al. Expression of the type I insulin-like growth factor is up-regulated in primary prostate cancer and commonly persists in metastatic disease Cancer Res. 2002; 62: 2942-2950.
  8. Petrylak D. P. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999; 54 (suppl. 6A): 30-35.
  9. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 1993; 71: 1098- 1109.
  10. Abrahamson P. A. Neuroendocrine differentation in prostatic carcinoma. Prostate 1999; 39 (2): 135-148.
  11. Small E. J., Vogelzang N. J. Second-line hormone therapy for advanced prostate cancer: a shifting paradigm. J. Clin. Oncol. 1997; 15: 382-388.
  12. Eisenberger M. A., Simon R., О'Dwyer P. J. et al. A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J. Clin. Oncol. 1985; 3: 827-845.
  13. Graft N., Shostac Y., Carey M. et al. A mechanism for hormoneindependent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med. 1999; 5 (3): 280-285.
  14. Green S., Furr B. Prospects for the treatment of endocrine-responsive tumors. Endocr. Relat. Cancer 1999; 6 (3): 349-371.
  15. Lein M., Yung K., Dinh L. К. et al. Synthetic inhibitor of metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate 2000; 43 (2): 77-82.
  16. Tjoa B. A., Lodge P., Salgaller M. L. et al. Dendritic-cell based immunotherapy for prostate cancer. J. Clin. Oncol. 1999; 49 (2): 117-128.
  17. Prima L. N., Meyers F. K. Treatment options in androgen-independent prostate cancer. Cancer Invest. 1999; 17 (2): 137- 144.
  18. Rosenthal M. A. Advances in the management of prostate cancer. Austral. N. Z. J. Med. 2000; 30 (5): 593-399.
  19. Beer T. M., Pierce W. C., Lowe B. A. et al. Phase II study of weekly Docetaxel (Taxotere) in hormone refractory metastatic prostate cancer. Proc. ASCO 2000; abstr. 1368.!
  20. De Mulder P., Sclken J., Sternberg C. Treatment/options in hormone resistant prostate cancer. Ann. Oncol. 2002; 13 (suppl. 4): 95-102.
  21. Logothetis С. J. Docetaxel in the integrated management of prostatae cancer - current applications and future promise. Oncology 2002; 16 (6, suppl. 6): 63-72.
  22. Tannock I. F., Osoba D., Stockier M. R. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996; 14: 1756-1764.
  23. Kantoff P. W., Halabi S., Conoway M. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group В 9182 study. J. Clin. Oncol. 1999; 17: 2506-2513.
  24. Жумагазин Ж. Д. Химиотерапия и иммунотерапия рака предстательной железы: Дис. ... д-ра мед. наук. 1996. 159- 173.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2005 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies